US Patent

US11400090 — Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder

Method of Use · Assigned to Institute of Cancer Research Royal Cancer Hospital · Expires 2038-10-29 · 12y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a medicament for treating or preventing a cell proliferative disorder, used in a specific dosing schedule.

USPTO Abstract

The present invention provides a medicament for the treatment or prevention of a cell proliferative disorder, the medicament comprising as an active ingredient a compound represented by formula or a pharmaceutically acceptable salt thereof, wherein the medicament is used in such a manner that: (a) said compound or salt is administered twice weekly for 3 weeks, (b) administration of said compound or salt is paused for the following 1 week, and (c) steps (a) and (b) are subsequently repeated at least once.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4196 —

Patent Metadata

Patent number
US11400090
Jurisdiction
US
Classification
Method of Use
Expires
2038-10-29
Drug substance claim
No
Drug product claim
No
Assignee
Institute of Cancer Research Royal Cancer Hospital
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.